Cargando…
97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience
Autores principales: | Angelis, V., McFarlane, P., Cunningham, N., Gennatas, S., Johnston, S.R.D., Okines, A., McGrath, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106264/ http://dx.doi.org/10.1016/j.annonc.2021.03.111 |
Ejemplares similares
-
Translating breast cancer research into clinical practice — new approaches and better outcomes
por: Johnston, SRD
Publicado: (2006) -
Bariatric Surgical Services Within a Pandemic Can Continue Safely: the Initial Experience of a UK Centre of Excellence
por: Moussa, Osama, et al.
Publicado: (2021) -
Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer
por: Angelis, Vasileios, et al.
Publicado: (2020) -
Faxing ECGs from peripheral hospitals to Tertiary Paediatric Cardiology Units- Is it Safe and Sustainable?
por: McGrath, Sam, et al.
Publicado: (2014) -
COVID-19 led to a decline in climate and environmental concern: evidence from UK panel data
por: Beiser-McGrath, Liam F.
Publicado: (2022)